13 unknown, 4 recruiting, 2 not yet recruiting, 1 completed. 20 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Unknown 13, Recruiting 4, Not yet recruiting 2, Completed 1 |
| Phase 2 | 14 | Unknown 11, Recruiting 2, Not yet recruiting 1 |
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures Panitumumab-IRDye800 - Cancer, Chemotherapy | Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 6 | 2026-11-01 | 2026-11-05 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC Glutathione, PD1 Inhibitor, Chemotherapy - Non-Small Cell Lung Cancer, Chemotherapy | Phase 1 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 80 | 2025-06-01 | 2025-08-07 |
| Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental - Metastatic Gastric Adenocarcinoma, Second Line | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 45 | 2024-04-01 | 2026-04-09 |
| Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA SNP, Palbociclib 125mg, Bevacizumab - Cancer, Solid Tumor | Phase 1 | Recruiting | Lebanese University | 50 | 2023-02-15 | 2024-03-12 |
| Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) Chemotherapy, Adoptive TKC transfer therapy - Advanced Non-small Cell Lung Cancer, Chemotherapy | Phase 1 | Unknown | suhaichuan | 20 | 2021-08-08 | 2021-08-04 |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug) - Cervical Cancer, Chemotherapy | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2020-04-15 | 2020-03-19 |
| Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy Pembrolizumab Combined With Chemotherapy - Gut Microbiota, NSCLC | Phase 1 / Phase 2 | Unknown | Xiaorong Dong | 40 | 2020-04-01 | 2020-04-03 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Palbociclib, Rivaroxaban, SNP - Cancer, Solid Tumor | Phase 1 | Unknown | Lebanese University | 500 | 2019-02-01 | 2023-10-06 |
| DCHA as Postremission Therapy for AML With t(8;21) Chemotherapy - Chemotherapy | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2018-01-01 | 2018-03-05 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer Chemotherapy, Precision Cells - Precision Cell Immunotherapy, Chemotherapy | Phase 1 / Phase 2 | Unknown | Ningbo Cancer Hospital | 40 | 2016-08-01 | 2016-10-07 |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Chemotherapy, precision cells - Precision Cells, Chemotherapy | Phase 1 / Phase 2 | Unknown | Shanghai International Medical Center | 40 | 2016-08-01 | 2016-09-02 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer Chemotherapy, Precision Cell Immunotherapy - Precision Cell Immunotherapy, Chemotherapy | Phase 1 / Phase 2 | Unknown | Ningbo Cancer Hospital | 40 | 2016-08-01 | 2016-10-07 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer Chemotherapy, Precision Cells - Precision Cell Immunotherapy, Chemotherapy | Phase 1 / Phase 2 | Unknown | Shanghai International Medical Center | 40 | 2016-08-01 | 2016-09-02 |
| A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy EW02 - Breast Cancer, Chemotherapy | Phase 1 / Phase 2 | Unknown | Tri-Service General Hospital (TSGH) | 60 | 2007-11-01 | 2007-11-08 |
| Garlic in Patients With Febrile Neutropenia Solgar Israel, Placebo capsules - Chemotherapy, Neutropenia | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 120 | 2006-06-01 | 2013-07-08 |
| Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen capecitabine - Breast Neoplasms, Chemotherapy | Phase 1 / Phase 2 | Unknown | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 46 | 2006-03-01 | 2006-05-18 |
| Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction Irinotecan - Unspecified Adult Solid Tumor, Chemotherapy | Phase 1 | Completed | Pfizer | 2009-08-14 |
Neoplasms (5) · Breast Neoplasms (4) · Cardiovascular Diseases (2) · Inflammation (2) · Lung Neoplasms (2) · Neutropenia (2) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Fever (1) · Immune System Diseases (1)
Neoplasms by Site (7) · Neoplasms (6) · Pathological Conditions, Signs and Symptoms (5) · Urogenital Diseases (5) · Breast Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lung Diseases (4) · Pathologic Processes (4) · Respiratory Tract Diseases (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Urogenital Neoplasms (4) · Digestive System Diseases (3) · Genital Diseases (3)
Drug Therapy (9) · Immune Checkpoint Inhibitors (2) · palbociclib (2) · Bevacizumab (1) · Capecitabine (1) · Glutathione (1) · Irinotecan (1) · Radiation Dose Hypofractionation (1) · Ramucirumab (1) · Rivaroxaban (1) · Tegafur (1) · Trifluridine (1) · entinostat (1) · gimeracil (1) · irinotecan sucrosofate (1)
Lebanese University (2) · Ningbo Cancer Hospital (2) · Shanghai International Medical Center (2) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · Butantan Institute (1) · Chinese PLA General Hospital (1) · Hadassah Medical Organization (1) · National Health Research Institutes, Taiwan (1) · Peking Union Medical College Hospital (1) · Pfizer (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The First Affiliated Hospital of Zhengzhou University (1) · Tri-Service General Hospital (TSGH) (1) · University of Alabama at Birmingham (1) · West China Hospital (1)
China (9) · Lebanon (2) · Taiwan (2) · United States (2) · Brazil (1) · France (1) · Israel (1)
Huajun Jin (2) · Jiangtao Wang (2) · Nehman Makdissy, Professor (2) · Qijun Qian (2) · Helong Zhang (1) · Hongqian Guo, PhD (1) · Ke Hu, MD (1) · Li Yu, MD. Ph.D (1) · Nai-Jung Chiang, MD-PhD (1) · Naiyan Han (1) · Ricardo Palacios, MD, PhD (1) · Teresa Boitano, MD (1) · Tsu-Yi Chao, M.D (1)
PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26036623, PMID 26615328, PMID 27091418, PMID 27871319, PMID 40468090